Cellebrite DI (NASDAQ:CLBT) Cut to “Hold” at Wall Street Zen

by · The Cerbat Gem

Cellebrite DI (NASDAQ:CLBT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. lowered their target price on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, May 12th. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 target price on shares of Cellebrite DI in a report on Friday, June 6th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.43.

Get Our Latest Analysis on CLBT

Cellebrite DI Stock Down 2.0%

CLBT opened at $13.70 on Friday. The business has a fifty day moving average of $15.52 and a 200 day moving average of $18.45. Cellebrite DI has a 52-week low of $11.90 and a 52-week high of $26.30. The stock has a market cap of $3.28 billion, a P/E ratio of -14.27, a PEG ratio of 2.82 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The company had revenue of $107.55 million during the quarter, compared to analysts’ expectations of $109.36 million. During the same quarter in the previous year, the business earned $0.08 EPS. Cellebrite DI’s revenue was up 20.0% compared to the same quarter last year. Equities analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CLBT. Signaturefd LLC raised its position in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after acquiring an additional 819 shares in the last quarter. Assetmark Inc. bought a new position in shares of Cellebrite DI in the 1st quarter worth $33,000. Catalyst Capital Advisors LLC bought a new position in shares of Cellebrite DI in the 1st quarter worth $51,000. Virtus Advisers LLC bought a new position in shares of Cellebrite DI in the 1st quarter worth $63,000. Finally, Hennessy Advisors Inc. bought a new position in shares of Cellebrite DI in the 2nd quarter worth $83,000. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Featured Stories